Literature DB >> 27609437

Polycystic ovary syndrome and arrhythmic risk: the role of comorbidities and the prevalence of interatrial block.

Vincenzo Russo1, Gerardo Nigro2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27609437      PMCID: PMC5331361          DOI: 10.14744/AnatolJCardiol.2016.7297

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


× No keyword cloud information.
To the Editor, We have read with great interest the article by Bayır PT et al. (1) entitled “Assessment of atrial electromechanical interval and P wave dispersion in patients with polycystic ovary syndrome” recently published in Anatol J Cardiol 2016; 16: 100-5. The authors, investigating several echocardiographic (atrial electromechanical delay) and electrocardiographic parameters (P wave duration and dispersion) predictive of atrial fibrillation, showed an increased interatrial and intra-atrial conduction times in patients affected by polycystic ovary syndrome (PCOS) compared to healthy women group without clinical and laboratory features of PCOS. As the authors underline, the PCOS study population showed increased left atrium diameters and impaired diastolic function parameters; these findings support the hypothesis that increased atrial conduction times might not be related per se to PCOS but might be a consequence of relatively impaired left ventricular diastolic function and atrial enlargement. According to our opinion, this is a point of pivotal importance, because it may affect the arrhythmologic management of patients with PCOS and, in particular, the timing of careful monitoring for early detection of atrial fibrillation. We suggest the authors to perform their electrocardiographic and echocardiographic analyses in PCOS patients with no structural or functional echocardiograp- hic abnormalities, including the atrial mechanical function evaluation, and to correlate their results to the serum testosterone and estradiol levels (2). Furthermore, it should be noted that in other clinical scenarios, P-wave parameters, other than P-wave dispersion, are risk predictors of supraventricular arrhythmias and notably of stroke (3–5). Specifically, we refer to P-wave duration—the hallmark of interatrial block (IAB)—that Bayır PT et al. (1) measured but not discussed, thereby losing the opportunity to first report the prevalence of IAB in a PCOS population. Moreover, by analyzing the P-wave morphology in inferior leads, they could identify the advanced form of IAB, characterized by biphasic (+/–) P wave in leads II, III, and aVF, which is a stronger electrocardiographic predictor of atrial fibrillation and embolic stroke than P wave duration.
  5 in total

1.  Letter to the Editor--Prevalence of interatrial block during lifetime.

Authors:  Vincenzo Russo; Marco Marano
Journal:  Heart Rhythm       Date:  2015-12-29       Impact factor: 6.343

Review 2.  [Interatrial block: an under-recognized electrocardiographic diagnosis with important clinical-therapeutic implications].

Authors:  Riccardo Proietti; Vincenzo Russo; Antonio Sagone; Maurizio Viecca; David H Spodick
Journal:  G Ital Cardiol (Rome)       Date:  2014-10

3.  Electrocardiographic indexes of arrhythmic risk in polycystic ovary syndrome.

Authors:  V Russo; M Marano
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016       Impact factor: 3.507

4.  Interatrial blocks. A separate entity from left atrial enlargement: a consensus report.

Authors:  Antonio Bayés de Luna; Pyotr Platonov; Francisco G Cosio; Iwona Cygankiewicz; Carlos Pastore; Rafa Baranowski; Antoni Bayés-Genis; Josep Guindo; Xavier Viñolas; Javier Garcia-Niebla; Raimundo Barbosa; Shlomo Stern; David Spodick
Journal:  J Electrocardiol       Date:  2012-09       Impact factor: 1.438

5.  Assessment of atrial electromechanical interval and P wave dispersion in patients with polycystic ovary syndrome.

Authors:  Pınar Türker Bayır; Ümit Güray; Serkan Duyuler; Burcu Demirkan; Oya Kayaalp; Selçuk Kanat; Yeşim Güray
Journal:  Anatol J Cardiol       Date:  2015-03-23       Impact factor: 1.596

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.